TET2 mutations in Ph-negative myeloproliferative neoplasms: Identification of three novel mutations and relationship with clinical and laboratory findings

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Patriarca, Andrea ^a   Colaizzo, Donatella ^b   Tiscia, Gianluca ^b   Spadano, Raffaele ^a   Di Zacomo, Silvia ^a   Spadano, Antonio ^a   Villanova, Ida ^a   Margaglione, Maurizio ^c   Grandone, Elvira ^b   Dragani, Alfredo ^a  

^a SPIRITO SANTO HOSPITAL   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; TET2 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ONCOPROTEIN; TET2 PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; AGED; ALLELE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BUDD CHIARI SYNDROME; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DNA SEQUENCE; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MONOCYTOSIS; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; THROMBOTIC THROMBOCYTOPENIC PURPURA; COHORT ANALYSIS; GENETICS; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PHILADELPHIA 1 CHROMOSOME; THROMBOSIS; VERY ELDERLY; COMPLICATION; MYELOPROLIFERATIVE DISORDERS;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME; PROTO-ONCOGENE PROTEINS; THROMBOSIS;

EID: 84878740538     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/929840     Document Type: Article

References (20)

1. Tefferi A., Vainchenker W., Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. Journal of Clinical Oncology 2011 29 5 573 582 2-s2.0-79952075257 10.1200/JCO.2010.29.8711
2. Abdel-Wahab O., Mullally A., Hedvat C., Garcia-Manero G., Patel J., Wadleigh M., Malinge S., Yao J., Kilpivaara O., Bhat R., Huberman K., Thomas S., Dolgalev I., Heguy A., Paietta E., Le Beau M. M., Beran M., Tallman M. S., Ebert B. L., Kantarjian H. M., Stone R. M., Gilliland D. G., Crispino J. D., Levine R. L., Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009 114 1 144 147 2-s2.0-67651065502 10.1182/blood-2009-03-210039
3. Delhommeau F., Dupont S., Della Valle V., Mutation in TET2 in myeloid cancers. New England Journal of Medicine 2009 360 2289 2301
4. Couronné L., Lippert E., Andrieux J., Kosmider O., Radford-Weiss I., Penther D., Dastugue N., Mugneret F., Lafage M., Gachard N., Nadal N., Bernard O. A., Nguyen-Khac F., Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 2010 24 1 201 203 2-s2.0-74249096163 10.1038/leu.2009.169
5. Langemeijer S. M. C., Kuiper R. P., Berends M., Knops R., Aslanyan M. G., Massop M., Stevens-Linders E., Van Hoogen P., Van Kessel A. G., Raymakers R. A. P., Kamping E. J., Verhoef G. E., Verburgh E., Hagemeijer A., Vandenberghe P., De Witte T., Van Der Reijden B. A., Jansen J. H., Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature Genetics 2009 41 7 838 842 2-s2.0-67649876132 10.1038/ng.391
6. Tefferi A., Pardanani A., Lim K. H., Abdel-Wahab O., Lasho T. L., Patel J., Gangat N., Finke C. M., Schwager S., Mullally A., Li C. Y., Hanson C. A., Mesa R., Bernard O., Delhommeau F., Vainchenker W., Gilliland D. G., Levine R. L., TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009 23 5 905 911 2-s2.0-67349124376 10.1038/leu.2009.47
7. Tefferi A., Levine R. L., Lim K. H., Abdel-Wahab O., Lasho T. L., Patel J., Finke C. M., Mullally A., Li C. Y., Pardanani A., Gilliland D. G., Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009 23 5 900 904 2-s2.0-67349145955 10.1038/leu.2009.37
8. Tefferi A., Lim K. H., Abdel-Wahab O., Lasho T. L., Patel J., Patnaik M. M., Hanson C. A., Pardanani A., Gilliland D. G., Levine R. L., Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009 23 7 1343 1345 2-s2.0-67650924270 10.1038/leu.2009.59
9. Abdel-Wahab O., Genetics of the myeloproliferative neoplasms. Current Opinion in Hematology 2011 18 117 123
10. Tefferi A., Vardiman J. W., Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008 22 1 14 22 2-s2.0-38349101871 10.1038/sj.leu.2404955
11. Patriarca A., Pompetti F., Malizia R., Iuliani O., Di Marzio I., Spadano A., Dragani A., Is the absence of JAK2V617F mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients. Blood Transfusion 2010 8 1 21 27 2-s2.0-74549226161 10.2450/2009.0004-09
12. Nguyen-Khac F., Lesty C., Eclache V., Couronné L., Kosmider O., Andrieux J., Collonge-Rame M. A., Penther D., Lafage M., Bilhou-Nabera C., Chapiro E., Mozziconacci M. J., Mugneret F., Gachard N., Nadal N., Lippert E., Struski S., Dastugue N., Cabrol C., Bernard O. A., Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes and Cancer 2010 49 10 919 927 2-s2.0-77957868375 10.1002/gcc.20802
13. Saint-Martin C., Leroy G., Delhommeau F., Panelatti G., Dupont S., James C., Plo I., Bordessoule D., Chomienne C., Delannoy A., Devidas A., Gardembas-Pain M., Isnard F., Plumelle Y., Bernard O., Vainchenker W., Najman A., Bellanné-Chantelot C., Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 2009 114 8 1628 1632 2-s2.0-70149101696 10.1182/blood-2009-01-197525
14. Kosmider O., Gelsi-Boyer V., Ciudad M., Racoeur C., Jooste V., Vey N., Quesnel B., Fenaux P., Bastie J. N., Beyne-Rauzy O., Stamatoulas A., Dreyfus F., Ifrah N., De Botton S., Vainchenker W., Bernard O. A., Birnbaum D., Fontenay M., Solary E., TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009 94 12 1676 1681 2-s2.0-73149094518 10.3324/haematol.2009.011205
15. Kohlmann A., Klein H. U., Weissmann S., The Interlaboratory Robustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia 2011 25 1840 1848
16. Voso M. T., Fabiani E., Piciocchi A., Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine. Leukemia 2011 25 1910 1913
17. Ko M., Huang Y., Jankowska A. M., Pape U. J., Tahiliani M., Bandukwala H. S., An J., Lamperti E. D., Koh K. P., Ganetzky R., Liu X. S., Aravind L., Agarwal S., MacIejewski J. P., Rao A., Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010 468 7325 839 843 2-s2.0-78650175023 10.1038/nature09586
18. Pollyea D. A., Raval A., Kusler B., Gotlib J. R., Alizadeh A. A., Mitchell B. S., Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. Journal of Hematology & Oncology 2011 29 157 160
19. Szpurka H., Jankowska A. M., Makishima H., Bodo J., Bejanyan N., Hsi E. D., Sekeres M. A., Maciejewski J. P., Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leukemia Research 2010 34 8 969 973 2-s2.0-77953616961 10.1016/j.leukres.2010.02.033
20. Jankowska A. M., Szpurka H., Tiu R. V., Makishima H., Afable M., Huh J., O'Keefe C. L., Ganetzky R., McDevitt M. A., Maciejewski J. P., Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/ myeloproliferative neoplasms. Blood 2009 113 25 6403 6410 2-s2.0-67650588639 10.1182/blood-2009-02-205690